Show simple item record

dc.contributor.authorMøller, Christina Tanem
dc.contributor.authorTafjord, Gunnar
dc.contributor.authorBlindheim, Augun Jodis
dc.contributor.authorBerge, Viktor
dc.contributor.authorFosså, Sophie Dorothea
dc.contributor.authorKulle, Bettina
dc.date.accessioned2024-02-14T15:27:00Z
dc.date.available2024-02-14T15:27:00Z
dc.date.created2023-11-28T13:01:52Z
dc.date.issued2023
dc.identifier.citationScandinavian Journal of Urology. 2023, 58 101-108.en_US
dc.identifier.issn2168-1805
dc.identifier.urihttps://hdl.handle.net/11250/3117659
dc.description.abstractBefore immunotherapy became part of the management of metastatic bladder cancer (mBC), systemic anti-cancer treatment comprised primarily of platinum-based chemotherapy. The objective of this study was to describe the characteristics, the initial management, overall survival (OS) and hospitalisations of patients with mBC before 2018 when immunotherapy for mBC was introduced in Norway. Material and methods: It is a nationwide population-based study of primary mBC patients (diagnosed 2008-16). Descriptive statistics were applied and stratified for four initial management options (≤150 days after BC diagnosis): chemotherapy, major local treatment (cystectomy/pelvic radiotherapy), multimodal treatment (chemotherapy and local) and no anti-cancer treatment beyond transurethral resection of bladder tumour (untreated). Group differences were evaluated by Chi-square and Kruskal–Wallis test; OS was estimated with Kaplan–Meier. Results: Of the 305 patients included, 76 (25%) patients had chemotherapy, 46 (15%) patients had major local treatment, 21 (7%) patients had multimodal treatment and 162 (53%) patients were untreated. Median OS ranged from 2.3 months (untreated) to 9.8 months (chemotherapy). Patients who received treatment had a higher rate of hospitalisation, with a median stay of three to four times that of untreated patients. Conclusion: Before immunotherapy, more than 50% of patients with primary mBC did not receive any initial anti-cancer therapy and had a poor survival. Patients treated with chemotherapy had inferior median OS compared to those treated with comparable systemic strategies in contemporary trials. Our results provide a basis for future research on treatment and survival after the introduction of immunotherapy for mBC, aiming to improve the care and outcome of patients with mBC.en_US
dc.language.isoengen_US
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleInitial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norwayen_US
dc.title.alternativeInitial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norwayen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.source.pagenumber101-108en_US
dc.source.volume58en_US
dc.source.journalScandinavian Journal of Urologyen_US
dc.identifier.doi10.2340/sju.v58.5923
dc.identifier.cristin2203816
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse-Ikkekommersiell 4.0 Internasjonal